Maximus C.F. Yeung , Tsun Fong , Anthony P.Y. Liu , Ronald C.K. Chan , Angela Z. Chan , W.H. Lau , Johann Lok , Gloria Y. Gao , S.Y. Leung , Tony W.H. Shek
{"title":"皮肤纤维肉瘤隆突的综合临床病理和多组学特征显示PDGFD融合是一种独特的分子亚型,具有更好的生存率。","authors":"Maximus C.F. Yeung , Tsun Fong , Anthony P.Y. Liu , Ronald C.K. Chan , Angela Z. Chan , W.H. Lau , Johann Lok , Gloria Y. Gao , S.Y. Leung , Tony W.H. Shek","doi":"10.1016/j.modpat.2025.100792","DOIUrl":null,"url":null,"abstract":"<div><div>Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive superficial mesenchymal neoplasm characterized by <em>COL1A1::PDGFB</em> fusion. Recently, <em>PDGFD</em> has been identified as a less common fusion partner. However, the clinicopathological and molecular differences between <em>PDGFD</em>-fusion and <em>PDGFB</em>-fusion DFSP remain largely unknown. In this study of 363 DFSP, we found 10 cases with <em>PDGFD</em> fusion, including 2 with a previously undescribed partner involving the <em>EMILIN1</em> gene. Multiomics analysis showed distinct transcriptomics, epigenomics, and copy number features for <em>PDGFD</em>-fusion DFSP versus <em>PDGFB</em>-fusion DFSP. <em>PDGFD</em>-fusion DFSP had higher <em>PDGFD</em> expression and virtually no <em>PDGFB</em> expression. Both clustered into the DFSP epigenomic cluster but formed a distinct subcluster with differential methylation affecting fibroblast migration genes. Copy number analysis revealed that <em>PDGFD</em>-fusion DFSP formed a distinct subgroup with a generally copy number–neutral profile and better survival than <em>PDGFB</em>-fusion DFSP that was dominated by amplification at translocation sites in chromosomes 17 and 22. Pooled analysis of 39 cases (incorporating 29 from the literature) revealed that <em>PDGFD</em>-fusion DFSP was more common in women (71.8% vs 42.4%, <em>P</em> < .001), occurred at a lower age (median, 37 years vs 45 years, <em>P</em> < .01), and had a higher chance of occurrence at the breast (25.6% vs 2.3%, <em>P</em> < .001). <em>PDGFD</em>-fusion DFSP also tended to center predominantly in the subcutis (63.6% vs 30%, <em>P</em> < .001), had a circumscribed border (50% vs 19.2%, <em>P</em> < .001), was smaller in size (3 cm vs 3.5 cm, <em>P</em> = .017), and had a lower mitotic count (median, 1 vs 3 per 10 high-power fields, <em>P</em> = .03). Overall, our study provided detailed multiomics characterization of <em>PDGFD</em>-fusion DFSP with significant clinicopathological and diagnostic implications.</div></div>","PeriodicalId":18706,"journal":{"name":"Modern Pathology","volume":"38 9","pages":"Article 100792"},"PeriodicalIF":7.1000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive Clinicopathological and Multiomics Characterization of Dermatofibrosarcoma Protuberans Revealed PDGFD Fusion as Distinct Molecular Subtype With Better Survival\",\"authors\":\"Maximus C.F. Yeung , Tsun Fong , Anthony P.Y. Liu , Ronald C.K. Chan , Angela Z. Chan , W.H. Lau , Johann Lok , Gloria Y. Gao , S.Y. Leung , Tony W.H. Shek\",\"doi\":\"10.1016/j.modpat.2025.100792\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive superficial mesenchymal neoplasm characterized by <em>COL1A1::PDGFB</em> fusion. Recently, <em>PDGFD</em> has been identified as a less common fusion partner. However, the clinicopathological and molecular differences between <em>PDGFD</em>-fusion and <em>PDGFB</em>-fusion DFSP remain largely unknown. In this study of 363 DFSP, we found 10 cases with <em>PDGFD</em> fusion, including 2 with a previously undescribed partner involving the <em>EMILIN1</em> gene. Multiomics analysis showed distinct transcriptomics, epigenomics, and copy number features for <em>PDGFD</em>-fusion DFSP versus <em>PDGFB</em>-fusion DFSP. <em>PDGFD</em>-fusion DFSP had higher <em>PDGFD</em> expression and virtually no <em>PDGFB</em> expression. Both clustered into the DFSP epigenomic cluster but formed a distinct subcluster with differential methylation affecting fibroblast migration genes. Copy number analysis revealed that <em>PDGFD</em>-fusion DFSP formed a distinct subgroup with a generally copy number–neutral profile and better survival than <em>PDGFB</em>-fusion DFSP that was dominated by amplification at translocation sites in chromosomes 17 and 22. Pooled analysis of 39 cases (incorporating 29 from the literature) revealed that <em>PDGFD</em>-fusion DFSP was more common in women (71.8% vs 42.4%, <em>P</em> < .001), occurred at a lower age (median, 37 years vs 45 years, <em>P</em> < .01), and had a higher chance of occurrence at the breast (25.6% vs 2.3%, <em>P</em> < .001). <em>PDGFD</em>-fusion DFSP also tended to center predominantly in the subcutis (63.6% vs 30%, <em>P</em> < .001), had a circumscribed border (50% vs 19.2%, <em>P</em> < .001), was smaller in size (3 cm vs 3.5 cm, <em>P</em> = .017), and had a lower mitotic count (median, 1 vs 3 per 10 high-power fields, <em>P</em> = .03). Overall, our study provided detailed multiomics characterization of <em>PDGFD</em>-fusion DFSP with significant clinicopathological and diagnostic implications.</div></div>\",\"PeriodicalId\":18706,\"journal\":{\"name\":\"Modern Pathology\",\"volume\":\"38 9\",\"pages\":\"Article 100792\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0893395225000882\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0893395225000882","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
Comprehensive Clinicopathological and Multiomics Characterization of Dermatofibrosarcoma Protuberans Revealed PDGFD Fusion as Distinct Molecular Subtype With Better Survival
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive superficial mesenchymal neoplasm characterized by COL1A1::PDGFB fusion. Recently, PDGFD has been identified as a less common fusion partner. However, the clinicopathological and molecular differences between PDGFD-fusion and PDGFB-fusion DFSP remain largely unknown. In this study of 363 DFSP, we found 10 cases with PDGFD fusion, including 2 with a previously undescribed partner involving the EMILIN1 gene. Multiomics analysis showed distinct transcriptomics, epigenomics, and copy number features for PDGFD-fusion DFSP versus PDGFB-fusion DFSP. PDGFD-fusion DFSP had higher PDGFD expression and virtually no PDGFB expression. Both clustered into the DFSP epigenomic cluster but formed a distinct subcluster with differential methylation affecting fibroblast migration genes. Copy number analysis revealed that PDGFD-fusion DFSP formed a distinct subgroup with a generally copy number–neutral profile and better survival than PDGFB-fusion DFSP that was dominated by amplification at translocation sites in chromosomes 17 and 22. Pooled analysis of 39 cases (incorporating 29 from the literature) revealed that PDGFD-fusion DFSP was more common in women (71.8% vs 42.4%, P < .001), occurred at a lower age (median, 37 years vs 45 years, P < .01), and had a higher chance of occurrence at the breast (25.6% vs 2.3%, P < .001). PDGFD-fusion DFSP also tended to center predominantly in the subcutis (63.6% vs 30%, P < .001), had a circumscribed border (50% vs 19.2%, P < .001), was smaller in size (3 cm vs 3.5 cm, P = .017), and had a lower mitotic count (median, 1 vs 3 per 10 high-power fields, P = .03). Overall, our study provided detailed multiomics characterization of PDGFD-fusion DFSP with significant clinicopathological and diagnostic implications.
期刊介绍:
Modern Pathology, an international journal under the ownership of The United States & Canadian Academy of Pathology (USCAP), serves as an authoritative platform for publishing top-tier clinical and translational research studies in pathology.
Original manuscripts are the primary focus of Modern Pathology, complemented by impactful editorials, reviews, and practice guidelines covering all facets of precision diagnostics in human pathology. The journal's scope includes advancements in molecular diagnostics and genomic classifications of diseases, breakthroughs in immune-oncology, computational science, applied bioinformatics, and digital pathology.